Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a gene-editing company’s disclosures can feel like lab work. CRISPR Therapeutics’ 10-K alone weaves R&D spending, milestone payments, and clinical data into hundreds of pages. Our platform turns that complexity into clarity: CRISPR Therapeutics SEC filings explained simply.
Stock Titan’s AI combs every CRISPR Therapeutics quarterly earnings report 10-Q filing to surface cash-burn trends, collaboration revenue, and pipeline progress, while side-by-side charts deliver CRISPR Therapeutics earnings report filing analysis in minutes. Need to react quickly to trial updates? You’ll see CRISPR Therapeutics 8-K material events explained within moments of hitting EDGAR. For annual deep dives, our summary of the CRISPR Therapeutics annual report 10-K simplified highlights manufacturing scale-up plans and key risk factors.
- Instant alerts on CRISPR Therapeutics Form 4 insider transactions real-time, so you can track every CRISPR Therapeutics executive stock transactions Form 4 and spot sentiment shifts.
- Clear answers to “How do I read the CRISPR Therapeutics proxy statement executive compensation?” with plain-English AI notes.
- Guided walkthroughs for understanding CRISPR Therapeutics SEC documents with AI, saving hours of manual review.
Whether you’re checking CRISPR Therapeutics insider trading Form 4 transactions before a catalyst event or validating dilution risk, our tool delivers comprehensive coverage, real-time updates, and context that matters to gene-editing investors.
On 09/17/2025 Samarth Kulkarni, Chief Executive Officer and a Director of CRISPR Therapeutics AG (CRSP), reported a transaction on Form 4 showing he donated 6,000 common shares to a donor-advised fund. The Form 4 shows 201,004 shares beneficially owned directly after the transaction and 85,622 shares indirectly held through the Kulkarni 2023 GRAT. The filing is signed on 09/19/2025 and notes the donation as the reason for the disposition; the reported price is $0.00, indicating a charitable transfer rather than a sale for proceeds.
Samarth Kulkarni, Chief Executive Officer and director of CRISPR Therapeutics AG (CRSP), had 25,000 restricted stock units vest on 08/16/2025, each converting to one common share. To satisfy tax withholding required by the company's RSU Settlement Policy, the reporting person sold 13,081 shares on 08/18/2025 at a price of $58.15 per share. After these transactions the reporting person directly beneficially owns 207,004 common shares and indirectly owns 85,622 common shares through the Kulkarni 2023 GRAT. The sale was described as mandated to cover tax withholding and not a discretionary trade.
CRISPR Therapeutics director Douglas A. Treco reported open-market activity on 08/06/2025, purchasing and selling shares of CRSP. The filing discloses an open-market purchase of 20,000 common shares and a reported disposition of 22,000 common shares. The filing lists a weighted average price of $57.03 and notes the sales occurred in multiple transactions at prices ranging from $56.92 to $57.16. The report states the purchases were made in accordance with the issuer's trading policies.
The form identifies Treco as a director and was submitted through an attorney-in-fact. The filing contains no financial results or forward guidance; it documents only the insider transactions and the price range for the reported sales.
CRISPR Therapeutics (Nasdaq: CRSP) filed an 8-K reporting new in-vivo cardiovascular data.
CTX310: Phase 1 trial shows up to 82% triglyceride and 86% LDL-C reductions at 0.8 mg/kg, with no clinically significant liver-enzyme changes.
CTX320: Phase 1 enrollment ongoing; next clinical update shifted to H1 2026 to incorporate emerging Lp(a) insights.
CTX340: IND/CTA-enabling studies progressing for refractory hypertension.
The company highlights validated surrogate endpoints, a favorable safety profile, and includes customary forward-looking statement disclaimers.
FAQ
What is the current stock price of Crispr Therapeut (CRSP)?
What is the market cap of Crispr Therapeut (CRSP)?
